AbbVie filed suit against Galderma alleging infringement of patented dermal filler syringe designs. The litigation centers on proprietary syringe engineering—likely covering needle gauge, plunger mechanics, or delivery systems that differentiate premium filler products in the market.
Regulatory
AbbVie Sues Galderma Over Patented Dermal Filler Syringe Designs
Patent litigation over syringe technology could affect filler supply and pricing dynamics.
1-YEAR MOVE
ABBV▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
Patent litigation over syringe design could reshape filler supply chains and pricing.
For practices, syringe patent disputes are typically long-running and rarely result in immediate supply disruption, but they signal competitive tension over product differentiation in the filler category. If AbbVie prevails or secures an injunction, Galderma could face redesign costs or temporary supply constraints on certain filler lines (Restylane, Volbella, etc.). Conversely, a Galderma win strengthens its design freedom. Practices should monitor case progress and maintain relationships with both manufacturers' account teams to understand any potential SKU changes or supply implications.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.